2382896-07-1
Chemical Structure
Sibeprenlimab
Synonym(s): VIS649
- CAS No.: 2382896-07-1
- Formula:N/A
- Molecular Weight:(146.36 kDa)
IUPAC Name: 2-((2aR,4S,6aR,7aR,9aR,9bR,10R,12R,13S,15R,15aR)-15-hydroxy-3,3,9a,10,15a-pentamethyl-4-(((2R,3S,4R,5S)-3,4,5-trihydroxytetrahydro-2H-pyran-2-yl)oxy)-2,2a,3,4,5,6,8,9,9a,9b,10,11,12,13,15,15a-hexadecahydro-7H-12,14a-epoxycyclopropa[1',8a']naphtho[2',1':4,5]indeno[2,1-b]oxepin-13-yl)propan-2-yl acetate
SMILES: [Sibeprenlimab]
Biological Activity: Sibeprenlimab (VIS649) is a humanized IgG2 monoclonal antibody which inhibits a proliferation-inducing ligand (APRIL). Sibeprenlimab suppresses pathogenic immunoglobulins (IgA and IgM), while preserving antibody responses to mRNA-based vaccines against SARS-COV-2. Sibeprenlimab reduces urinary protein-to-creatinine ratio (UPCR) and glomerular filtration rate (GFR). Sibeprenlimab is promising for the research of IgA nephropathy (IgAN)[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Sibeprenlimab | 99.82% | Sibeprenlimab (VIS649) is a humanized IgG2 monoclonal antibody which inhibits a proliferation-inducing ligand (APRIL). Sibeprenlimab suppresses pathogenic immunoglobulins (IgA and IgM), while preserving antibody responses to mRNA-based vaccines against SARS-COV-2. Sibeprenlimab reduces urinary protein-to-creatinine ratio (UPCR) and glomerular filtration rate (GFR). Sibeprenlimab is promising for the research of IgA nephropathy (IgAN). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Mohit Mathur, et al. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VIS649 (Sibeprenlimab), an APRIL-Neutralizing IgG2 Monoclonal Antibody, in Healthy Volunteers. Kidney Int Rep. 2022 Feb 8;7(5):993-1003. [Content Brief]
- [2]. Mathur M, et al. A PRoliferation-Inducing Ligand (APRIL) in the Pathogenesis of Immunoglobulin A Nephropathy: A Review of the Evidence. J Clin Med. 2023 Nov 4;12(21):6927. [Content Brief]
- [3]. Refardt J, et al. Arginine or Hypertonic Saline-Stimulated Copeptin to Diagnose AVP Deficiency. N Engl J Med. 2023 Nov 16;389(20):1877-1887. [Content Brief]
